Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate Pregabalin Efficacy in the Treatment of Behavioral and Psychological Symptoms of Dementia in Patients With Alzheimer’S Disease Publisher



Maleki L1 ; Mohammadian F2 ; Panahishokouh M3 ; Mohebbi N1, 4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Psychiatry, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Clinical Pharmacy, Faculty of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran

Source: Frontiers in Neuroscience Published:2024


Abstract

Background: Behavioral and Psychological Symptoms of Dementia (BPSD) are common during Alzheimer’s disease and cause severe problems for patients and their caregivers. Objectives: To assess the therapeutic efficacy of Pregabalin in comparison with a placebo in treating BPSD in patients with Alzheimer’s disease (AD) visiting the memory and cognition clinic of Roozbeh Psychiatric Hospital in Tehran, Iran. Methods: A 12-week double-blind, randomized comparison of Pregabalin and placebo treatments was conducted in 53 patients with DSM-V diagnosis of dementia of Alzheimer’s type. They were randomly assigned to receive Pregabalin (doses: 50 titrated up to 300 mg/day) or a placebo. Clinical response was evaluated using the Neuropsychiatric Inventory (NPI), and the Behavioral Pathology in AD Rating Scale (BEHAVE-AD) scores compared with baseline. Side effects were also recorded carefully. Results: Patients receiving Pregabalin had better outcomes in comparison with patients receiving a placebo regarding both NPI and BEHAVE-AD scores after 12 weeks (p-value = 0.009 for NPI and p-value = 0.003 for BEHAVE-AD). There was also a statistically significant decrease in the treatment group depression sub-score regarding NPI and BEHAVE-AD (respectively, p-value =0.000, 0.003). The caregiver burden sub-score of the NPI test was also lower in patients receiving pregabalin (p-value = 0.000). There was no statistically significant difference between the occurrence of adverse effects between the two groups (p-value = 1.00). Conclusion: Pregabalin at a dose of 300 mg/day was well tolerated and associated with reductions in the severity and frequency of behavioral symptoms in patients with AD. Pregabalin could be considered a favorable choice for treating BPSD in adults with mild to moderate stages of Alzheimer ‘s-type dementia, considering its befitting safety profile. Clinical trial registration: https://www.irct.ir/trial/52750, identifier IRCT20201201049553N1 Copyright © 2024 Maleki, Mohammadian, Panahishokouh and Mohebbi.
Related Docs
1. Long-Term Effects of Aβ42 Immunisation in Alzheimer's Disease: Follow-Up of a Randomised, Placebo-Controlled Phase I Trial, The Lancet (2008)
2. A Study on the Evaluation of Relationship Between the Predisposing Factors and Practice and Demographic Variables in Caregivers of Patients With Alzheimer's Diseases, Journal of Isfahan Medical School (2015)
3. Evaluation of the Effect of Donepezil on Cerebral Blood Flow Velocity in Alzheimer's Disease, Neurosciences (2010)
4. Effectiveness and Safety of Mlc601 in the Treatment of Mild to Moderate Alzheimer's Disease: A Multicenter, Randomized Controlled Trial, Dementia and Geriatric Cognitive Disorders Extra (2015)
5. Evaluation the Effect of Donepezil on Cerebral Blood Flow Velocity in Alzheimer's Disease, Journal of Isfahan Medical School (2010)
6. Stress As a Challenge in Promoting Mental Health Among Dementia Caregivers, Journal of Education and Health Promotion (2020)
7. Novel Effects of Rosa Damascena Extract on Patients With Neurocognitive Disorder and Depression: A Clinical Trial Study, International Journal of Preventive Medicine (2018)
8. The Effect of Long-Term Pregabalin Administration on Memory of Rat in Object Recognition Task, Journal of Isfahan Medical School (2020)
Experts (# of related papers)
View all Related Experts
Majid Barekatain (2)
Ahmad Chitsaz (2)